Systemic mastocytosis (SM) is a hematological malignancy characterized by extracutaneous infiltration by atypical mast cells. Together with indolent SM, aggressive SM, and mast cell leukemia, the World Health Organization (WHO) recognizes another major disease subgroup: SM with an associated hematological neoplasm, which is characterized by the presence of a concurrent neoplasm, more commonly, a chronic myelomonocytic leukemia. While KIT D816V is commonly regarded as the driver mutation, the clinical presentation of SM is extremely varied. Treatment of SM might not be simple, but now more specific therapies tailored toward prognostic subgroups of patients have been developed. Here, we report a detailed description of clinical management and biological features of a systemic mastocytocis case associated with multiple hematologic non–mast cell lineage diseases.

A case report of systemic mastocytosis associated with multiple hematologic non-mast cell lineage diseases / Grifoni, F.I., Sciumè, M., Pravettoni, V., Ulivieri, F.M., Muratori, S., Fracchiolla, N.S., Tagliaferri, E., Gianelli, U., Migliorini, A.C., Cro, L., Pacilli, A., Mannelli, F., Baldini, L.. - In: HEMATOLOGICAL ONCOLOGY. - ISSN 1099-1069. - ELETTRONICO. - 37:(2019), pp. 205-211. [10.1002/hon.2605]

A case report of systemic mastocytosis associated with multiple hematologic non-mast cell lineage diseases

Pacilli, Annalisa;Mannelli, Francesco;Baldini, Luca
2019

Abstract

Systemic mastocytosis (SM) is a hematological malignancy characterized by extracutaneous infiltration by atypical mast cells. Together with indolent SM, aggressive SM, and mast cell leukemia, the World Health Organization (WHO) recognizes another major disease subgroup: SM with an associated hematological neoplasm, which is characterized by the presence of a concurrent neoplasm, more commonly, a chronic myelomonocytic leukemia. While KIT D816V is commonly regarded as the driver mutation, the clinical presentation of SM is extremely varied. Treatment of SM might not be simple, but now more specific therapies tailored toward prognostic subgroups of patients have been developed. Here, we report a detailed description of clinical management and biological features of a systemic mastocytocis case associated with multiple hematologic non–mast cell lineage diseases.
2019
37
205
211
Goal 3: Good health and well-being
Grifoni, Federica Irene; Sciumè, Mariarita; Pravettoni, Valerio; Ulivieri, Fabio Massimo; Muratori, Simona; Fracchiolla, Nicola Stefano; Tagliaferri, ...espandi
File in questo prodotto:
File Dimensione Formato  
Grifoni Hematol Oncol 2019.pdf

accesso aperto

Tipologia: Pdf editoriale (Version of record)
Licenza: Solo lettura
Dimensione 1.21 MB
Formato Adobe PDF
1.21 MB Adobe PDF

I documenti in FLORE sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificatore per citare o creare un link a questa risorsa: https://hdl.handle.net/2158/1499307
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 3
  • ???jsp.display-item.citation.isi??? 2
social impact